Related references
Note: Only part of the references are listed.The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
J. W. Mouton et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
Sujata M. Bhavnani et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections
J. A. Passarell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo
Johan W. Mouton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections
A. K. Meagher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Pharmacodynamics of tobramycin in patients with cystic fibrosis
JW Mouton et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid
WA Craig
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections
SLCE Buijk et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
PG Ambrose et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
